Concepts (221)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Breast Neoplasms | 40 | 2023 | 20824 | 1.100 |
Why?
|
| Comprehensive Health Care | 2 | 2016 | 127 | 0.640 |
Why?
|
| Mastectomy | 7 | 2018 | 1793 | 0.630 |
Why?
|
| Oncology Service, Hospital | 1 | 2016 | 57 | 0.540 |
Why?
|
| Patient Care Team | 2 | 2016 | 2531 | 0.450 |
Why?
|
| Paclitaxel | 10 | 2021 | 1708 | 0.440 |
Why?
|
| Carcinoma, Intraductal, Noninfiltrating | 2 | 2018 | 948 | 0.400 |
Why?
|
| Carcinoma, Ductal, Breast | 2 | 2018 | 1100 | 0.400 |
Why?
|
| Mammaplasty | 3 | 2016 | 1204 | 0.400 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 16 | 2021 | 11525 | 0.400 |
Why?
|
| Environment Design | 1 | 2013 | 178 | 0.390 |
Why?
|
| Epothilones | 5 | 2013 | 44 | 0.360 |
Why?
|
| Inservice Training | 1 | 2013 | 392 | 0.360 |
Why?
|
| Biomedical Technology | 1 | 2012 | 220 | 0.360 |
Why?
|
| Pharmacoepidemiology | 1 | 2012 | 323 | 0.340 |
Why?
|
| Granulocyte Colony-Stimulating Factor | 3 | 2016 | 648 | 0.300 |
Why?
|
| Critical Pathways | 2 | 2022 | 476 | 0.290 |
Why?
|
| Referral and Consultation | 5 | 2018 | 3531 | 0.280 |
Why?
|
| Neoplasm Staging | 8 | 2018 | 11031 | 0.270 |
Why?
|
| Medical Oncology | 3 | 2022 | 2267 | 0.260 |
Why?
|
| Drug Costs | 1 | 2012 | 1105 | 0.250 |
Why?
|
| Music Therapy | 1 | 2006 | 102 | 0.240 |
Why?
|
| Communication | 1 | 2016 | 3750 | 0.210 |
Why?
|
| Deoxycytidine | 4 | 2012 | 826 | 0.210 |
Why?
|
| Gene Expression Profiling | 2 | 2018 | 9445 | 0.210 |
Why?
|
| Fluorouracil | 4 | 2012 | 1619 | 0.200 |
Why?
|
| Neoplasms | 8 | 2022 | 21696 | 0.200 |
Why?
|
| Taxoids | 4 | 2008 | 666 | 0.190 |
Why?
|
| Mastectomy, Segmental | 2 | 2018 | 956 | 0.190 |
Why?
|
| Diagnostic Imaging | 1 | 2015 | 3508 | 0.190 |
Why?
|
| Peripheral Nervous System Diseases | 2 | 2018 | 685 | 0.180 |
Why?
|
| Isoquinolines | 1 | 2001 | 366 | 0.180 |
Why?
|
| Chemotherapy, Adjuvant | 8 | 2018 | 3480 | 0.180 |
Why?
|
| Electronic Health Records | 1 | 2016 | 4468 | 0.180 |
Why?
|
| Neutropenia | 3 | 2016 | 895 | 0.170 |
Why?
|
| Antineoplastic Agents | 8 | 2012 | 13693 | 0.170 |
Why?
|
| Tegafur | 1 | 1998 | 49 | 0.170 |
Why?
|
| Quality of Health Care | 1 | 2014 | 4369 | 0.160 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2015 | 8949 | 0.160 |
Why?
|
| Stress, Physiological | 1 | 2006 | 1403 | 0.160 |
Why?
|
| Antibiotics, Antineoplastic | 1 | 2001 | 692 | 0.150 |
Why?
|
| Uracil | 1 | 1998 | 165 | 0.150 |
Why?
|
| Female | 43 | 2023 | 380193 | 0.140 |
Why?
|
| Antineoplastic Agents, Phytogenic | 2 | 2016 | 624 | 0.140 |
Why?
|
| Receptors, Estrogen | 3 | 2023 | 2190 | 0.130 |
Why?
|
| Anthracyclines | 2 | 2008 | 288 | 0.130 |
Why?
|
| Receptors, Progesterone | 2 | 2018 | 1098 | 0.130 |
Why?
|
| Cancer Care Facilities | 2 | 2018 | 402 | 0.130 |
Why?
|
| Antimetabolites, Antineoplastic | 1 | 1998 | 640 | 0.120 |
Why?
|
| Adult | 27 | 2021 | 214052 | 0.120 |
Why?
|
| Drug Therapy | 1 | 2017 | 497 | 0.120 |
Why?
|
| Middle Aged | 29 | 2021 | 213390 | 0.120 |
Why?
|
| Neoplasms, Multiple Primary | 1 | 2018 | 604 | 0.120 |
Why?
|
| Phlebotomy | 1 | 2014 | 141 | 0.120 |
Why?
|
| Aged | 25 | 2023 | 163288 | 0.110 |
Why?
|
| Humans | 49 | 2023 | 744366 | 0.110 |
Why?
|
| Receptor, erbB-2 | 6 | 2021 | 2417 | 0.110 |
Why?
|
| Radiology | 2 | 2018 | 2099 | 0.110 |
Why?
|
| Vinblastine | 3 | 2003 | 502 | 0.110 |
Why?
|
| Trust | 1 | 2016 | 505 | 0.100 |
Why?
|
| Neoplasm Metastasis | 7 | 2021 | 4851 | 0.100 |
Why?
|
| Tubulin Modulators | 1 | 2012 | 111 | 0.100 |
Why?
|
| Neoplasm Invasiveness | 2 | 2018 | 3616 | 0.100 |
Why?
|
| Stress, Psychological | 1 | 2006 | 4245 | 0.090 |
Why?
|
| Pyrazoles | 1 | 2021 | 1972 | 0.090 |
Why?
|
| Drug Resistance, Neoplasm | 4 | 2010 | 5172 | 0.090 |
Why?
|
| Potassium | 1 | 2014 | 1336 | 0.090 |
Why?
|
| Postoperative Care | 1 | 2016 | 1487 | 0.090 |
Why?
|
| Attitude to Health | 1 | 2019 | 2052 | 0.090 |
Why?
|
| Quality Improvement | 2 | 2016 | 3749 | 0.090 |
Why?
|
| Sentinel Lymph Node Biopsy | 2 | 2004 | 710 | 0.080 |
Why?
|
| Neoadjuvant Therapy | 2 | 2018 | 2727 | 0.080 |
Why?
|
| Reoperation | 1 | 2018 | 4201 | 0.080 |
Why?
|
| Quality of Life | 3 | 2006 | 12802 | 0.080 |
Why?
|
| Mammography | 2 | 2018 | 2475 | 0.080 |
Why?
|
| Neoplasm Recurrence, Local | 3 | 2023 | 9240 | 0.080 |
Why?
|
| Doxorubicin | 6 | 2016 | 2234 | 0.070 |
Why?
|
| Interdisciplinary Communication | 1 | 2013 | 950 | 0.070 |
Why?
|
| Cohort Studies | 5 | 2018 | 40559 | 0.070 |
Why?
|
| Ambulatory Care Facilities | 1 | 2013 | 934 | 0.070 |
Why?
|
| Aged, 80 and over | 8 | 2018 | 57776 | 0.070 |
Why?
|
| Pilot Projects | 3 | 2019 | 8319 | 0.070 |
Why?
|
| Genetic Testing | 1 | 2018 | 3444 | 0.070 |
Why?
|
| Boston | 3 | 2014 | 9312 | 0.060 |
Why?
|
| Paroxetine | 1 | 2005 | 182 | 0.060 |
Why?
|
| Genital Neoplasms, Female | 1 | 2010 | 523 | 0.060 |
Why?
|
| Cyclophosphamide | 5 | 2016 | 2242 | 0.060 |
Why?
|
| Integrative Medicine | 1 | 2006 | 87 | 0.060 |
Why?
|
| Qualitative Research | 1 | 2013 | 2682 | 0.060 |
Why?
|
| Practice Guidelines as Topic | 2 | 2016 | 7282 | 0.060 |
Why?
|
| Radiation-Sensitizing Agents | 1 | 2005 | 358 | 0.060 |
Why?
|
| Young Adult | 5 | 2018 | 56429 | 0.060 |
Why?
|
| Biomedical Research | 1 | 2019 | 3309 | 0.060 |
Why?
|
| Drug Administration Schedule | 5 | 2018 | 4933 | 0.060 |
Why?
|
| Registries | 1 | 2018 | 8091 | 0.060 |
Why?
|
| Hot Flashes | 1 | 2005 | 316 | 0.050 |
Why?
|
| New England | 1 | 2006 | 1022 | 0.050 |
Why?
|
| Image Interpretation, Computer-Assisted | 1 | 2015 | 3326 | 0.050 |
Why?
|
| Time Factors | 6 | 2018 | 40075 | 0.050 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2017 | 8432 | 0.050 |
Why?
|
| Erythropoietin | 1 | 2005 | 726 | 0.050 |
Why?
|
| Antibodies, Monoclonal | 6 | 2003 | 9274 | 0.050 |
Why?
|
| Survivors | 1 | 2010 | 2291 | 0.050 |
Why?
|
| Neuroendocrine Tumors | 1 | 2005 | 594 | 0.040 |
Why?
|
| Alkylating Agents | 1 | 2000 | 139 | 0.040 |
Why?
|
| Nutrition Surveys | 1 | 2005 | 1660 | 0.040 |
Why?
|
| Mesna | 1 | 1998 | 66 | 0.040 |
Why?
|
| Lymphatic Metastasis | 2 | 2004 | 2924 | 0.040 |
Why?
|
| Adolescent | 3 | 2015 | 85779 | 0.040 |
Why?
|
| Feedback | 1 | 2022 | 795 | 0.040 |
Why?
|
| Prognosis | 2 | 2015 | 29060 | 0.040 |
Why?
|
| Ifosfamide | 1 | 1998 | 228 | 0.040 |
Why?
|
| Health Care Costs | 1 | 2010 | 3208 | 0.040 |
Why?
|
| Follow-Up Studies | 2 | 2015 | 39052 | 0.040 |
Why?
|
| Survival Rate | 1 | 2010 | 12788 | 0.030 |
Why?
|
| Obesity | 1 | 2018 | 12746 | 0.030 |
Why?
|
| Anemia | 1 | 2005 | 1503 | 0.030 |
Why?
|
| Stem Cell Factor | 1 | 1996 | 219 | 0.030 |
Why?
|
| Risk Assessment | 2 | 2018 | 23336 | 0.030 |
Why?
|
| Nitriles | 1 | 2021 | 955 | 0.030 |
Why?
|
| Lymph Nodes | 2 | 2004 | 3476 | 0.030 |
Why?
|
| Retrospective Studies | 6 | 2023 | 77460 | 0.030 |
Why?
|
| Mastocytosis | 1 | 1996 | 160 | 0.030 |
Why?
|
| Meningeal Neoplasms | 1 | 2003 | 1241 | 0.030 |
Why?
|
| Feasibility Studies | 2 | 2019 | 5077 | 0.030 |
Why?
|
| Patient Care Planning | 1 | 2019 | 921 | 0.030 |
Why?
|
| Neoplasm, Residual | 1 | 2018 | 973 | 0.030 |
Why?
|
| Feeding Behavior | 1 | 2005 | 3188 | 0.030 |
Why?
|
| Confidence Intervals | 1 | 2018 | 2971 | 0.030 |
Why?
|
| Medical Records | 1 | 2018 | 1413 | 0.030 |
Why?
|
| Observer Variation | 1 | 2018 | 2593 | 0.030 |
Why?
|
| Delivery of Health Care | 1 | 2010 | 5321 | 0.030 |
Why?
|
| Tumor Burden | 1 | 2018 | 1915 | 0.030 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 2 | 2000 | 5445 | 0.030 |
Why?
|
| Decision Making | 1 | 2005 | 3888 | 0.020 |
Why?
|
| Enzyme Inhibitors | 2 | 2001 | 3799 | 0.020 |
Why?
|
| Clinical Trials, Phase II as Topic | 1 | 2012 | 629 | 0.020 |
Why?
|
| Consensus | 1 | 2018 | 2960 | 0.020 |
Why?
|
| Mast Cells | 1 | 1996 | 1544 | 0.020 |
Why?
|
| Pyrimidines | 1 | 2021 | 2943 | 0.020 |
Why?
|
| Disease-Free Survival | 2 | 2013 | 6896 | 0.020 |
Why?
|
| Academic Medical Centers | 1 | 2018 | 2760 | 0.020 |
Why?
|
| Clinical Trials, Phase III as Topic | 1 | 2012 | 841 | 0.020 |
Why?
|
| Maximum Tolerated Dose | 1 | 2010 | 892 | 0.020 |
Why?
|
| Clinical Trials as Topic | 2 | 2019 | 7914 | 0.020 |
Why?
|
| Treatment Outcome | 6 | 2013 | 63107 | 0.020 |
Why?
|
| Tocopherols | 1 | 2005 | 43 | 0.020 |
Why?
|
| Colonic Neoplasms | 1 | 1998 | 2542 | 0.020 |
Why?
|
| Filgrastim | 1 | 2005 | 133 | 0.020 |
Why?
|
| Colorectal Neoplasms | 1 | 2005 | 6773 | 0.020 |
Why?
|
| Survival Analysis | 3 | 2003 | 10252 | 0.020 |
Why?
|
| Radiation Pneumonitis | 1 | 2005 | 104 | 0.020 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2012 | 10943 | 0.020 |
Why?
|
| Disease Management | 1 | 2015 | 2460 | 0.020 |
Why?
|
| Prospective Studies | 2 | 2006 | 53290 | 0.020 |
Why?
|
| Cisplatin | 2 | 2001 | 1662 | 0.020 |
Why?
|
| Quinazolines | 1 | 2010 | 1356 | 0.010 |
Why?
|
| Salvage Therapy | 1 | 2010 | 1275 | 0.010 |
Why?
|
| B-Lymphocyte Subsets | 1 | 2004 | 246 | 0.010 |
Why?
|
| Ovariectomy | 1 | 2005 | 661 | 0.010 |
Why?
|
| Neoplasms, Hormone-Dependent | 1 | 2005 | 415 | 0.010 |
Why?
|
| Carotenoids | 1 | 2005 | 624 | 0.010 |
Why?
|
| Nutrition Assessment | 1 | 2005 | 723 | 0.010 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2013 | 6539 | 0.010 |
Why?
|
| Brain Neoplasms | 1 | 2003 | 8861 | 0.010 |
Why?
|
| Tumor Cells, Cultured | 2 | 2000 | 6313 | 0.010 |
Why?
|
| Age Factors | 1 | 2018 | 18373 | 0.010 |
Why?
|
| Risk Factors | 3 | 2018 | 72296 | 0.010 |
Why?
|
| Topoisomerase I Inhibitors | 1 | 2001 | 65 | 0.010 |
Why?
|
| Premenopause | 1 | 2005 | 1033 | 0.010 |
Why?
|
| Placebos | 1 | 2005 | 1676 | 0.010 |
Why?
|
| Ovarian Neoplasms | 1 | 1998 | 4839 | 0.010 |
Why?
|
| Erythrocyte Transfusion | 1 | 2005 | 565 | 0.010 |
Why?
|
| Cell Division | 2 | 1999 | 4569 | 0.010 |
Why?
|
| Incidence | 1 | 2018 | 20952 | 0.010 |
Why?
|
| Radiotherapy, Adjuvant | 1 | 2005 | 1771 | 0.010 |
Why?
|
| Mechlorethamine | 1 | 2000 | 136 | 0.010 |
Why?
|
| Carmustine | 1 | 2000 | 137 | 0.010 |
Why?
|
| Cross-Over Studies | 1 | 2005 | 2029 | 0.010 |
Why?
|
| Polyethylene Glycols | 1 | 2005 | 1182 | 0.010 |
Why?
|
| Male | 6 | 2012 | 350115 | 0.010 |
Why?
|
| Combined Modality Therapy | 2 | 2003 | 8642 | 0.010 |
Why?
|
| Radiotherapy Dosage | 1 | 2005 | 2879 | 0.010 |
Why?
|
| Disease Progression | 2 | 2007 | 13286 | 0.010 |
Why?
|
| Case-Control Studies | 1 | 2016 | 21748 | 0.010 |
Why?
|
| Infusions, Intravenous | 1 | 2003 | 2274 | 0.010 |
Why?
|
| Melphalan | 1 | 2000 | 431 | 0.010 |
Why?
|
| Liposomes | 1 | 2001 | 759 | 0.010 |
Why?
|
| Fatty Acids | 1 | 2005 | 1809 | 0.010 |
Why?
|
| Proportional Hazards Models | 1 | 2012 | 12356 | 0.010 |
Why?
|
| Databases, Factual | 1 | 2012 | 7730 | 0.010 |
Why?
|
| Recombinant Proteins | 1 | 2005 | 6621 | 0.010 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2018 | 20130 | 0.010 |
Why?
|
| ROC Curve | 1 | 2003 | 3528 | 0.010 |
Why?
|
| Decision Support Techniques | 1 | 2005 | 1956 | 0.010 |
Why?
|
| Patient Compliance | 1 | 2005 | 2684 | 0.010 |
Why?
|
| Neoplasms, Experimental | 1 | 2000 | 1276 | 0.010 |
Why?
|
| Severity of Illness Index | 1 | 2012 | 15535 | 0.010 |
Why?
|
| Algorithms | 2 | 2005 | 13882 | 0.010 |
Why?
|
| Flow Cytometry | 1 | 2004 | 5974 | 0.010 |
Why?
|
| Drug Resistance | 1 | 1999 | 1608 | 0.010 |
Why?
|
| Lung Neoplasms | 1 | 1998 | 13104 | 0.010 |
Why?
|
| Multivariate Analysis | 1 | 2005 | 12244 | 0.010 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2018 | 35425 | 0.010 |
Why?
|
| Double-Blind Method | 1 | 2005 | 12025 | 0.010 |
Why?
|
| Spleen | 1 | 1996 | 2362 | 0.010 |
Why?
|
| Heart Diseases | 1 | 2003 | 2789 | 0.010 |
Why?
|
| Cell Survival | 1 | 2000 | 5882 | 0.010 |
Why?
|
| Leukocytes, Mononuclear | 1 | 1996 | 1837 | 0.010 |
Why?
|
| Cardiomyopathies | 1 | 2001 | 1912 | 0.010 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2005 | 9955 | 0.010 |
Why?
|
| Recurrence | 1 | 1999 | 8340 | 0.000 |
Why?
|
| Reproducibility of Results | 1 | 2005 | 19905 | 0.000 |
Why?
|
| Predictive Value of Tests | 1 | 2003 | 15078 | 0.000 |
Why?
|
| T-Lymphocytes | 1 | 2004 | 10183 | 0.000 |
Why?
|
| Cell Membrane | 1 | 1996 | 3749 | 0.000 |
Why?
|
| Models, Biological | 1 | 1999 | 9584 | 0.000 |
Why?
|
| Skin | 1 | 1996 | 4372 | 0.000 |
Why?
|
| Cell Differentiation | 1 | 1996 | 11486 | 0.000 |
Why?
|
| Mice | 1 | 2000 | 81201 | 0.000 |
Why?
|
| Animals | 1 | 2000 | 168768 | 0.000 |
Why?
|
Concepts
(221)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(73)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_
Same Department
People in same department with this person.
Explore
_
Physical Neighbors
People whose addresses are nearby this person.
_